Khilko Natalya, Bourne Patricia
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA.
Int J Surg Pathol. 2007 Jul;15(3):233-41. doi: 10.1177/1066896907302116.
Breast carcinoma is one of the most common malignancies in women, and its carcinogenesis is still unknown. The role of microsatellite instability (MSI) in breast carcinogenesis has been inconsistent in the literature. Here we studied the expression of 2 mismatch repair genes, hMLH1 and hMSH2, in 211 cases of intraductal (DCIS; 90 cases) and invasive ductal carcinoma (121 cases) of the breast by immunohistochemical analysis; and evaluated its relationship with cytokeratin (CK) subtypes, along with expression of ER-alpha (138 cases positive, 73 cases negative); PR (118 cases positive, 93 cases negative), and HER-2/neu (47 cases positive, 164 cases negative); and clinical features such as patient age (157 cases>50 years, 54 cases<50 years), tumor size (31 cases of IDC>2 cm, 90 cases of IDC<2 cm), tumor grade (87 cases high nuclear grade, 124 case non-high grade), and lymph node metastasis (38 cases of IDC positive, 74 cases of IDC negative, 9 cases of IDC with no available data on lymph node status). For CK subtypes, 167 cases were classified as luminal subtype (expressing CK8 and/or CK18, negative for CK5/6, CK14, and CK17) and 44 cases were classified as nonluminal (most of them belonged to basal/stem subtype, expressing CK5/6, and/or CK14, and/or CK17). No typical or atypical medullary carcinoma was included in this study. Our results showed that no loss of nuclear expression of either hMLH1 or hMSH2 was identified in any of the 211 cases of DCIS or IDC regardless of the various pathological and clinical factors, suggesting that hMLH1 or hMSH2 may not play an essential role in the majority of cases of the breast carcinoma.
乳腺癌是女性最常见的恶性肿瘤之一,其致癌机制尚不清楚。微卫星不稳定性(MSI)在乳腺癌致癌过程中的作用在文献中一直存在争议。在此,我们通过免疫组化分析研究了211例乳腺导管内癌(DCIS;90例)和浸润性导管癌(121例)中2种错配修复基因hMLH1和hMSH2的表达情况;评估了其与细胞角蛋白(CK)亚型的关系,以及雌激素受体α(ER-α,138例阳性,73例阴性)、孕激素受体(PR,118例阳性,93例阴性)和人表皮生长因子受体2/neu(HER-2/neu,47例阳性,164例阴性)的表达情况;以及患者年龄(157例>50岁,54例<50岁)、肿瘤大小(31例浸润性导管癌>2 cm,90例浸润性导管癌<2 cm)、肿瘤分级(87例高核分级,124例非高分级)和淋巴结转移(38例浸润性导管癌阳性,74例浸润性导管癌阴性,9例浸润性导管癌无淋巴结状态可用数据)等临床特征。对于CK亚型,167例被分类为管腔亚型(表达CK8和/或CK18,CK5/6、CK14和CK17阴性),44例被分类为非管腔亚型(其中大多数属于基底/干细胞亚型,表达CK5/6和/或CK14和/或CK17)。本研究未纳入典型或非典型髓样癌。我们的结果显示,在211例DCIS或浸润性导管癌中,无论各种病理和临床因素如何,均未发现hMLH1或hMSH2核表达缺失,这表明hMLH1或hMSH2在大多数乳腺癌病例中可能不发挥重要作用。